Policy & Regulation
Carisma Therapeutics names new director
2 April 2024 -

Carisma Therapeutics Inc. (Nasdaq: CARM), a US-based clinical-stage biopharmaceutical company, announced on Monday that it has named John Hohneker, MD as its new director.

Dr Hohneker has more than 30 years of extensive experience in drug development and leadership across the biotech and pharmaceutical sectors. Most recently, he served as president and chief executive officer of Anokion SA. He has also worked as the president of Research and Development at FORMA Therapeutics Inc and in roles of increasing responsibility at Novartis AG, which includes most recently as senior vice president and global head of Development, Immunology, and Dermatology. He has also served in positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome. Presently, he serves as the director of Curis, Inc., Sonata Therapeutics, Inc., and Trishula Therapeutics, Inc. He has earlier served as a member of the board of directors of Torque Therapeutics, Inc., Dimension Therapeutics, Inc., Cygnal Therapeutics, Inc., BioTheryX Inc., Evelo Biosciences, Inc., Humanigen, Inc. and Aravive, Inc.

Sanford Zweifach, chair of the Carisma board of directors, said, 'We are pleased to welcome John to the Carisma board of directors. I believe John's extensive track record of clinical development, strategic leadership, and public company board membership in the biopharmaceutical space will enable him to immediately support the company as it continues leading the field of engineered macrophage development.'